ATE500848T1 - Verfahren zur herstellung eines stabilen immunogenen produkts beinhaltend antigene- heterokomplexe aus tnf-aplha und einem trägerprotein - Google Patents
Verfahren zur herstellung eines stabilen immunogenen produkts beinhaltend antigene- heterokomplexe aus tnf-aplha und einem trägerproteinInfo
- Publication number
- ATE500848T1 ATE500848T1 AT06818201T AT06818201T ATE500848T1 AT E500848 T1 ATE500848 T1 AT E500848T1 AT 06818201 T AT06818201 T AT 06818201T AT 06818201 T AT06818201 T AT 06818201T AT E500848 T1 ATE500848 T1 AT E500848T1
- Authority
- AT
- Austria
- Prior art keywords
- heterocomplexes
- carrier protein
- aplha
- tnf
- antigen
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title abstract 2
- 108010078791 Carrier Proteins Proteins 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05300404 | 2005-05-24 | ||
| PCT/EP2006/005044 WO2007022813A2 (en) | 2005-05-24 | 2006-05-24 | A METHOD FOR PREPARING A STABLE IMMUNOGENIC PRODUCT COMPRISING ANTIGENIC HETEROCOMPLEXES OF TNFα AND A CARRIER PROTEIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE500848T1 true ATE500848T1 (de) | 2011-03-15 |
Family
ID=35746986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06818201T ATE500848T1 (de) | 2005-05-24 | 2006-05-24 | Verfahren zur herstellung eines stabilen immunogenen produkts beinhaltend antigene- heterokomplexe aus tnf-aplha und einem trägerprotein |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7887811B2 (de) |
| EP (1) | EP1888122B1 (de) |
| JP (1) | JP5061099B2 (de) |
| CN (1) | CN101222941A (de) |
| AT (1) | ATE500848T1 (de) |
| AU (1) | AU2006284248B2 (de) |
| BR (1) | BRPI0609932A2 (de) |
| CA (1) | CA2609572C (de) |
| DE (1) | DE602006020563D1 (de) |
| ES (1) | ES2382229T3 (de) |
| NZ (1) | NZ563526A (de) |
| WO (1) | WO2007022813A2 (de) |
| ZA (1) | ZA200710011B (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2244735A4 (de) | 2007-10-02 | 2011-02-23 | Avaxia Biologics Inc | Antikörpertherapie zur verwendung im verdauungstrakt |
| NZ629256A (en) * | 2009-12-22 | 2016-02-26 | Celldex Therapeutics Inc | Vaccine compositions |
| CN103347536A (zh) * | 2010-12-08 | 2013-10-09 | 尼奥瓦克斯公司 | 强灭活且仍高免疫原性的疫苗及其制备方法 |
| EP2462950A1 (de) | 2010-12-08 | 2012-06-13 | Neovacs | Stark inaktivierter und weiterhin hoch immunogener Impfstoff, sowie Verfahren zu seiner Herstellung |
| GB201106802D0 (en) | 2011-04-21 | 2011-06-01 | Allergy Therapeutics Ltd | Process for preparing vaccine composition |
| WO2013019889A2 (en) * | 2011-08-01 | 2013-02-07 | Avaxia Biologics, Inc. | Bovine polyclonal antibody specific for human tnf |
| US20150038454A1 (en) * | 2013-07-31 | 2015-02-05 | Mary Malast | Antimicrobial compositions and methods of use |
| US9733162B2 (en) | 2014-02-11 | 2017-08-15 | Ihor Turkevych | Universal system, method and solution for the acceleration of the process of fixing, dehydrating and clearing the structure of biological tissue |
| CN106478802B (zh) * | 2016-10-11 | 2019-08-09 | 浙江省人民医院 | TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用 |
| CN115594770B (zh) * | 2022-12-14 | 2023-04-07 | 上海惠盾因泰生物科技有限公司 | 一种针对人TNFα分子的类风湿关节炎治疗性疫苗的构建 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223395A (en) * | 1988-12-01 | 1993-06-29 | Centocor, Inc. | Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples |
| FI920131A0 (fi) * | 1989-07-14 | 1992-01-13 | Praxis Biolog Inc | Cytokin- och hormonbaerare foer konjugatvaccin. |
| US5578308A (en) * | 1990-02-12 | 1996-11-26 | Capiau; Carine | Glutaraldehyde and formalin detoxified bordetella toxin vaccine |
| DK96493D0 (da) | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| FR2812813B1 (fr) | 2000-08-09 | 2004-11-26 | Neovacs | Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires induits par des facteurs extracellulaires |
| ITMI20010571A1 (it) * | 2001-03-19 | 2002-09-19 | Grisotech S A | Vaccini assorbibili per via trans-mucosale |
| FR2828404B1 (fr) * | 2001-08-10 | 2005-07-15 | Neovacs | Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal |
| FR2844514B1 (fr) * | 2002-09-16 | 2007-10-19 | Neovacs | Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation |
-
2006
- 2006-05-24 NZ NZ563526A patent/NZ563526A/en not_active IP Right Cessation
- 2006-05-24 DE DE602006020563T patent/DE602006020563D1/de active Active
- 2006-05-24 CA CA2609572A patent/CA2609572C/en not_active Expired - Fee Related
- 2006-05-24 ES ES06818201T patent/ES2382229T3/es active Active
- 2006-05-24 CN CNA2006800259946A patent/CN101222941A/zh active Pending
- 2006-05-24 JP JP2008512775A patent/JP5061099B2/ja not_active Expired - Fee Related
- 2006-05-24 AU AU2006284248A patent/AU2006284248B2/en not_active Ceased
- 2006-05-24 US US11/915,044 patent/US7887811B2/en not_active Expired - Fee Related
- 2006-05-24 BR BRPI0609932-7A patent/BRPI0609932A2/pt not_active IP Right Cessation
- 2006-05-24 AT AT06818201T patent/ATE500848T1/de not_active IP Right Cessation
- 2006-05-24 EP EP06818201A patent/EP1888122B1/de not_active Not-in-force
- 2006-05-24 WO PCT/EP2006/005044 patent/WO2007022813A2/en not_active Ceased
-
2007
- 2007-11-20 ZA ZA200710011A patent/ZA200710011B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007022813A2 (en) | 2007-03-01 |
| CA2609572A1 (en) | 2007-03-01 |
| CN101222941A (zh) | 2008-07-16 |
| WO2007022813A3 (en) | 2007-04-26 |
| ZA200710011B (en) | 2008-10-29 |
| AU2006284248A1 (en) | 2007-03-01 |
| US20080193473A1 (en) | 2008-08-14 |
| NZ563526A (en) | 2009-02-28 |
| JP5061099B2 (ja) | 2012-10-31 |
| EP1888122A2 (de) | 2008-02-20 |
| CA2609572C (en) | 2013-11-19 |
| EP1888122B1 (de) | 2011-03-09 |
| AU2006284248B2 (en) | 2010-10-07 |
| JP2008542227A (ja) | 2008-11-27 |
| BRPI0609932A2 (pt) | 2011-10-11 |
| ES2382229T3 (es) | 2012-06-06 |
| DE602006020563D1 (de) | 2011-04-21 |
| US7887811B2 (en) | 2011-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200710011B (en) | A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein | |
| ATE529409T1 (de) | Verfahren zur herstellung von kristallinen aripiprazolformen | |
| ATE267657T1 (de) | Verfahren zur herstellung von freiform-produkten | |
| DE502004009763D1 (de) | Verfahren zur herstellung von 1-buten | |
| WO2009010877A3 (en) | Conjugate purification | |
| EP1724357A4 (de) | Verfahren zur herstellung astaxanthinhaltiger lipide | |
| ATE425136T1 (de) | Verfahren zur herstellung substituierter 3-aryl- butyl-aminverbindungen | |
| ATE360653T1 (de) | Verfahren zur herstellung von polyisobutenen | |
| DE502005010038D1 (de) | Verfahren zur herstellung von 3-pentennitril | |
| ATE435209T1 (de) | Verfahren zur herstellung von montelukast-natrium | |
| ATE444950T1 (de) | Verfahren zur herstellung von 1-amino-3,5- dimethyladamantan-hydrochlorid | |
| ATE533019T1 (de) | Verfahren zur herstellung eines pulverförmigen produkts | |
| ATE491789T1 (de) | Verfahren zur herstellung gamma-carboxylierter proteine | |
| DE602006013151D1 (de) | Verfahren zur herstellung von polymermaleimiden | |
| EP1848580A4 (de) | Vorrichtung und verfahren zur herstellung von wellpappe und kaschiertem karton sowie darauf beruhende zusammensetzungen | |
| DE502005001841D1 (de) | Verfahren zur herstellung von 1,4-diphenylazetidinon-derivaten | |
| DE502005001997D1 (de) | Verfahren zur herstellung von silanisierten kohlenstoff-nanoröhren | |
| ATE542518T1 (de) | Verfahren zur herstellung eines zweifarbigen kosmetikums | |
| DE602006021324D1 (de) | Verfahren zur herstellung stabiler b-lymphozyten | |
| DE602005021110D1 (de) | Verfahren zur herstellung von n-piperidino-1,5-diphenylpyrazol-3-carboxamid-derivaten | |
| DE602005021380D1 (de) | Verfahren zur herstellung eines luftreifens | |
| DE502005007702D1 (de) | Verfahren zur herstellung von terrylen-3,4:11,12-t | |
| ATE374755T1 (de) | Verfahren zur herstellung von 1,3,5- triazincarbamaten und -harnstoffen | |
| TW200716167A (en) | Formulations and process for production of bordetella bronchiseptica P68 antigen and vaccines | |
| DE502004002810D1 (de) | Verfahren zur herstellung von copolymerisaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |